Device Intellanav_ep

Intellanav Mifi Xp

Payments companies reported to CMS as associated with Intellanav Mifi Xp. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$727associated payments (2023-2025)
19clinicians with associated payments
1company reporting

By year

2023 $213
2024 $207
2025 $307

Payments reported as associated with Intellanav Mifi Xp, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Clinical Cardiac Electrophysiology $413
Interventional Cardiology $161
Psychiatric/Mental Health (Nurse Practitioner) $28.83
Pediatric Surgery $28.82
Nurse Anesthetist, Certified Registered $28.82
Cardiovascular Disease $26.38

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Intellanav Mifi Xp

These are the largest totals companies reported as associated with Intellanav Mifi Xp. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Anthony Sonn Saint Louis, MO Interventional Cardiology $131.87
Apoor Patel Sugar Land, TX Clinical Cardiac Electrophysiology $72.45
Jose Cuellar Silva Webster, TX Clinical Cardiac Electrophysiology $69.95
Ragesh Panikkath San Luis Obispo, CA Clinical Cardiac Electrophysiology $65.32
Navinder Sawhney Escondido, CA Clinical Cardiac Electrophysiology $39.98
Timothy Ball Waco, TX Clinical Cardiac Electrophysiology $39.85
Meet Patel Middleburg Heights, OH Clinical Cardiac Electrophysiology $28.87
Rosaline Darty Shreveport, LA Psychiatric/Mental Health (Nurse Practitioner) $28.83
Paul Davis Shreveport, LA Interventional Cardiology $28.83
Sherman Wiggins Shreveport, LA Clinical Cardiac Electrophysiology $28.82

Prescribed Intellanav Mifi Xp?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.